O-014Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) – An ACCRU Network study. (20th June 2018) - Bekaii-Saab, T; Ou, F; Anderson, D; Ahn, D; Boland, P; Ciombor, K; Jacobs, N; Desnoyers, R; Cleary, J; Meyers, J; Chiorean, E; Pedersen, K; et al.